

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:)
HIROSHI KASE ET AL.) : Examiner: Sarah Pihonak
Appln. No.: 10/565,239) : Group Art Unit: 1627
Filed: January 19, 2006) : Conf. No.: 9168
For: PHARMACEUTICAL COMPOSITION)
U.S. Patent No.: 8,034,820 B2)
Issued: October 11, 2011) : December 12, 2011

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF CORRECTION
UNDER RULES 322 AND 323

Sir:

It is respectfully requested that a Certificate of Correction be issued by the Patent and Trademark Office due to errors which appear in the printed patent as a result of Patent and Trademark Office mistakes, and mistakes of a clerical, typographical, or minor character, which were not the fault of the Patent and Trademark Office.

The amount of \$100.00 to cover the statutory fee for such Certificate of Correction is being paid concurrently; please charge any deficiency in the fee, and credit any overpayment, to Deposit Account 06-1205.

Patentees' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Lawrence S. Perry/

Lawrence S. Perry
Attorney for Patentees
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
Facsimile: (212) 218-2200

FCHS_WS 7173972v1

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 8,034,820 B2
DATED : October 11, 2011
INVENTOR(S) : HIROSHI KASE ET AL.

Page 1 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ON THE TITLE PAGE [57] ABSTRACT:

Line 3, "comprises" should read --comprise--.

COLUMN 1:

Line 21, "a treatment" should read --treatment-- and
"carried out" should read --is carried out--;

Line 35, "38," should read --38--; and

Line 40, "38," should read --38--.

COLUMN 3:

Line 36, "drug for" should read --drug ¶ for-- (full margin).

COLUMN 4:

Line 60, "a serotonin" should read --serotonin--.

COLUMN 5:

Line 57, "thyl-3,17-dihydro--" should read --thyl-3,7-dihydro---; and
Line 66, "(52). The" should read --(52) The--.

COLUMN 9:

Line 32, "inhibitor simultaneously" should read --inhibitor ¶ simultaneously-- (full margin); and

Line 56, "drug for" should read --drug ¶ for-- (full margin).

MAILING ADDRESS OF SENDER:

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
(212) 218-2100 - Telephone
(212) 218-2200 - Facsimile

PATENT NO.:

US 8,034,820 B2

Form PTO/SB/44 (09-07)

FCHS_WS 7173972 v1

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 8,034,820 B2
DATED : October 11, 2011
INVENTOR(S) : HIROSHI KASE ET AL.

Page 2 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

COLUMN 11:

Line 6, "Published" should read --Published--.

COLUMN 18:

Line 50, "mociobemide" should read --moclobemide--.

COLUMN 19:

Line 5, "Psychiatric" should read --psychiatric--.

COLUMN 21:

Line 4, "Immobility" should read --immobility--.

COLUMN 22:

Line 6, "Immobility" should read --immobility--; and
Line 54, "decrease" should read --decreases--.

COLUMN 25:

Line 18, "Prescription" should be moved to following table, as title; and
Line 47, "Prescription" should be moved to following table, as title.

COLUMN 26:

Line 9, "Prescription" should be moved to following table, as title;
Line 37, "Prescription" should be moved to following table, as title; and
Line 67, "Prescription" should be moved to following table, as title.

MAILING ADDRESS OF SENDER:

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
(212) 218-2100 - Telephone
(212) 218-2200 – Facsimile

PATENT NO.:

US 8,034,820 B2

Form PTO/SB/44 (09-07)

FCHS_WS 7173972 v1

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 8,034,820 B2
DATED : October 11, 2011
INVENTOR(S) : HIROSHI KASE ET AL.

Page 3 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

COLUMN 27:

Line 28, "Prescription" should be moved to following table, as title; and
Line 56, "Prescription" should be moved to following table, as title.

COLUMN 28:

Line 10, "blending" should read --blending and--; and
Line 16, "Prescription" should be moved to following table, as title;
Ex. 10 Table,

"	Compound (I)	1 mg
	Purified soybean oil	200 mg
	Purified yolk lecithin	24 mg
	Glycerin for injection	50 mg
	Distilled water for injection	1.72 mL
		2.00 mL
		"

should read

--	Compound (I)	1 mg
	Purified soybean oil	200 mg
	Purified yolk lecithin	24 mg
	Glycerin for injection	50 mg
	Distilled water for injection	1.72 mL
		2.00 mL
		--;

Line 36, "blending" should read --blending and--;
Line 42, "Prescription" should be moved to following table, as title;

MAILING ADDRESS OF SENDER:

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
(212) 218-2100 - Telephone
(212) 218-2200 – Facsimile

PATENT NO.:

US 8,034,820 B2

Form PTO/SB/44 (09-07)

FCHS_WS 7173972 v1

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 8,034,820 B2
DATED : October 11, 2011
INVENTOR(S) : HIROSHI KASE ET AL.

Page 4 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Ex. 11 Table,

“	Bupropion	10 mg
	Purified soybean oil	200 mg
	Purified yolk lecithin	24 mg
	Glycerin for injection	50 mg
	Distilled water for injection	1.72 mL
		2.00 mL
		”

should read

--	Bupropion	10 mg
	Purified soybean oil	200 mg
	Purified yolk lecithin	24 mg
	Glycerin for injection	50 mg
	Distilled water for injection	1.72 mL
		2.00 mL
		--; and

Line 64, “blending” should read --blending and--.

COLUMN 29:

Line 4, Prescription” should be moved to following table, as title;
Ex. 12, Table,

“	Compound (I)	2 mg
	Clomipramine hydrochloride	25 mg
	Purified soybean oil	200 mg
	Purified yolk lecithin	24 mg
	Glycerin for injection	50 mg
	Distilled water for injection	1.62 mL
		2.00 mL
		”

MAILING ADDRESS OF SENDER:

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
(212) 218-2100 - Telephone
(212) 218-2200 – Facsimile

PATENT NO.:

US 8,034,820 B2

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 8,034,820 B2
DATED : October 11, 2011
INVENTOR(S) : HIROSHI KASE ET AL.

Page 5 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

should read

--	Compound (I)	2 mg
	Clomipramine hydrochloride	25 mg
	Purified soybean oil	200 mg
	Purified yolk lecithin	24 mg
	Glycerin for injection	50 mg
	Distilled water for injection	1.62 mL
		2.00 mL
		--;

Line 32, "Prescription" should be moved to following table, as title; and
Line 46, "provide" should read --provides--.

COLUMN 30:

Line 25, "fluoxetine," should read --fluoxetine--;
Line 38, "fluoxetine," should read --fluoxetine--; and
Line 51, "fluoxetine," should read --fluoxetine--.

MAILING ADDRESS OF SENDER:

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
(212) 218-2100 - Telephone
(212) 218-2200 - Facsimile

PATENT NO.: US 8,034,820 B2

Form PTO/SB/44 (09-07)

FCHS_WS 7173972 v1
FCHS_WS 7173972v1.doc